Glargine (n = 708) Detemir (n = 298) Glargine versus detemir
P value
  Baseline Follow-up Baseline Follow-up Baseline Follow-up
Insulin dose (IU)            
  n (%) 629 (89) 629 (89) 254 (85) 254 (85) 0.11 0.11
  Mean (SD) 31.2 (24.0) 31.3 (22.6) 32.0 (22.7) 36.6 (24.8) 0.68 <0.01
HbA1c (%)            
  n (%) 708 (100) 708 (100) 298 (100) 298 (100)    
  Mean (SD) 8.6 (1.4) 7.7 (1.2) 8.4 (1.4) 7.9 (1.2) <0.05 <0.05
  Change from baseline, mean (SD)   –0.9 (1.4)   –0.4 (1.4)   <0.001
  Patients with HbA1c < 7%, n (%) 70 (!0) 196 (28) 35 (12) 70 (23) 0.38 0.17
Fasting plasma glucose (mmol/L)            
  n (%) 512 (72) 458 (65) 222 (74) 171 (57) 0.48 0.48
  Mean (SD) 11.0 (3.9) 8.6 (3.0) 10.4 (3.5) 8.6 (2.8) <0.05 <0.05
  Change from baseline, mean (SD)   –2.6 (4.3)   –1.8 (3.8)   <0.05
Table 2: Baseline and follow-up insulin dose and glycemic parameters.